Johnson & Johnson (NYSE:JNJ) was downgraded by stock analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday. They presently have a $125.00 price objective on the stock, down from their previous price objective of $130.00. Barclays PLC’s target price suggests a potential upside of 11.13% from the stock’s current price. The analysts noted that the move was a valuation call.

A number of other equities research analysts have also commented on the company. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research report on Monday, August 22nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research report on Friday, August 5th. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. RBC Capital Markets set a $133.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Wednesday, November 9th. Finally, Bank of America Corp. reiterated a “hold” rating and set a $126.00 price target on shares of Johnson & Johnson in a report on Monday. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $121.02.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded down 0.57% during mid-day trading on Tuesday, reaching $112.48. 7,799,649 shares of the company were exchanged. The stock’s 50-day moving average is $115.85 and its 200-day moving average is $118.43. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07. The company has a market cap of $306.01 billion, a P/E ratio of 19.74 and a beta of 0.75.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. During the same period last year, the company posted $1.49 EPS. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post $6.72 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $0.80 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 annualized dividend and a yield of 2.84%. Johnson & Johnson’s payout ratio is currently 56.64%.

WARNING: This story was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/29/johnson-johnson-jnj-rating-lowered-to-equal-weight-at-barclays-plc.html.

In related news, Director Charles Prince purchased 875 shares of the firm’s stock in a transaction that occurred on Friday, October 21st. The shares were acquired at an average price of $114.11 per share, with a total value of $99,846.25. Following the purchase, the director now directly owns 26,520 shares in the company, valued at $3,026,197.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.11% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Ancora Inverness LLC raised its position in Johnson & Johnson by 10.3% in the first quarter. Ancora Inverness LLC now owns 40,858 shares of the company’s stock worth $4,421,000 after buying an additional 3,806 shares in the last quarter. King Wealth Management Group LLC raised its position in Johnson & Johnson by 2.4% in the first quarter. King Wealth Management Group LLC now owns 13,648 shares of the company’s stock worth $1,477,000 after buying an additional 314 shares in the last quarter. Investec Asset Management North America Inc. raised its position in Johnson & Johnson by 20.4% in the first quarter. Investec Asset Management North America Inc. now owns 99,581 shares of the company’s stock worth $10,775,000 after buying an additional 16,869 shares in the last quarter. Investec Asset Management LTD raised its position in Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock worth $546,454,000 after buying an additional 1,665,644 shares in the last quarter. Finally, Ropes Wealth Advisors LLC raised its position in Johnson & Johnson by 8.0% in the first quarter. Ropes Wealth Advisors LLC now owns 55,976 shares of the company’s stock worth $6,057,000 after buying an additional 4,161 shares in the last quarter. 64.13% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.